BPC-157 Eye Drops Reverse Corneal Anesthesia and Heal Corneal Lesions in Rats
BPC-157 applied as eye drops fully counteracted corneal numbness, healed corneal lesions, and restored tear production after topical anesthetic use in rats.
Quick Facts
What This Study Found
BPC-157 eye drops (0.4 μg/eye) fully counteracted tetracaine and oxybuprocaine corneal effects — restoring sensitivity, healing lesions, and normalizing tear production — even when the NO system was blocked.
Key Numbers
BPC-157 0.4 ug/eye; full counteraction of corneal insensitivity, lesions, tear reduction; effective with L-NAME or L-arginine co-administration
How They Did This
Controlled rat study measuring corneal sensitivity (Cochet-Bonnet esthesiometer), corneal lesions (fluorescein staining), and tear volume (Schirmer test) after anesthetic application with BPC-157 and NO pathway modulators.
Why This Research Matters
Corneal anesthetics are widely used in ophthalmology but cause temporary damage. A peptide eye drop that accelerates recovery could improve patient comfort and safety after eye procedures.
The Bigger Picture
This extends BPC-157 research into ophthalmology, demonstrating its cytoprotective and healing properties in a new tissue context — consistent with its broader wound-healing profile.
What This Study Doesn't Tell Us
Rat model only; single BPC-157 dose tested; no long-term safety data for ocular BPC-157 use; mechanism beyond NO pathway involvement not fully elucidated.
Questions This Raises
- ?Could BPC-157 eye drops be used clinically to accelerate recovery after ophthalmic procedures?
- ?What is the optimal BPC-157 concentration for human ocular applications?
- ?Does BPC-157 protect against corneal damage from repeated or prolonged anesthetic use?
Trust & Context
- Key Stat:
- Full counteraction BPC-157 reversed all three anesthetic effects: corneal numbness, lesions, and reduced tear volume
- Evidence Grade:
- Well-controlled animal study with multiple validated outcome measures and NO pathway investigation, but limited to rats with a single peptide dose.
- Study Age:
- Published in 2020; BPC-157 ocular applications represent a newer research direction within the broader BPC-157 literature.
- Original Title:
- Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats.
- Published In:
- Acta clinica Croatica, 59(3), 394-406 (2020)
- Authors:
- Mirković, Ivan, Kralj, Tamara(3), Lozić, Marin, Stambolija, Vasilije, Kovačević, Josip, Vrdoljak, Luka, Zlatar, Mirna, Milanović, Kristina, Drmić, Domagoj, Predović, Jurica, Masnec, Sanja, Jurjević, Matija, Bušić, Mladen, Seiwerth, Sven, Kokot, Antonio, Sikirić, Predrag
- Database ID:
- RPEP-05002
Evidence Hierarchy
Frequently Asked Questions
Can BPC-157 help eyes recover from anesthesia?
In rat studies, BPC-157 eye drops fully reversed corneal numbness, healed surface damage, and restored tear production after topical anesthetic use.
How does BPC-157 work in the eye?
BPC-157 interacts with the nitric oxide system to protect and heal corneal tissue, counteracting anesthetic-induced damage even when NO pathways are blocked.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05002APA
Mirković, Ivan; Kralj, Tamara; Lozić, Marin; Stambolija, Vasilije; Kovačević, Josip; Vrdoljak, Luka; Zlatar, Mirna; Milanović, Kristina; Drmić, Domagoj; Predović, Jurica; Masnec, Sanja; Jurjević, Matija; Bušić, Mladen; Seiwerth, Sven; Kokot, Antonio; Sikirić, Predrag. (2020). Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats.. Acta clinica Croatica, 59(3), 394-406. https://doi.org/10.20471/acc.2020.59.03.02
MLA
Mirković, Ivan, et al. "Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats.." Acta clinica Croatica, 2020. https://doi.org/10.20471/acc.2020.59.03.02
RethinkPeptides
RethinkPeptides Research Database. "Pentadecapeptide BPC 157 shortens duration of tetracaine- an..." RPEP-05002. Retrieved from https://rethinkpeptides.com/research/mirkovic-2020-pentadecapeptide-bpc-157-shortens
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.